Publications by authors named "Christopher Scrase"

Claim this Profile
R
Radiotherapy quality assurance for the PEACE 1 trial: An individual case review analysis.
Najlaa Alyamani, Enrico Clementel, Paul Sargos, Pierre Blanchard, Stephane Supiot, Christopher Scrase

Radiother Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial.
Alison Tree, Clare Griffin, Isabel Syndikus, Alison Birtle, Ananya Choudhury, Christopher Scrase

Int J Radiat Oncol Biol Phys· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016).
John N Staffurth, Joanne S Haviland, Anna Wilkins, Isabel Syndikus, Vincent Khoo, Christopher Scrase

Eur Urol Oncol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease.
Michel Bolla, Anouk Neven, Philippe Maingon, Christian Carrie, Ana Boladeras, Christopher D Scrase

J Clin Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial.
Christopher M Nutting, Clare L Griffin, Paul Sanghera, Bernadette Foran, Matthew Beasley, Christopher Scrase

Eur J Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
Ruth E Langley, Duncan C Gilbert, Trinh Duong, Noel W Clarke, Matthew Nankivell, Christopher D Scrase

Lancet· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial.
Julia Murray, Sarah Gulliford, Clare Griffin, Anna Wilkins, Isabel Syndikus, Christopher Scrase

Clin Transl Radiat Oncol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.
Julia Murray, Clare Griffin, Sarah Gulliford, Isabel Syndikus, John Staffurth, Christopher Scrase

Radiother Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL).
David Dearnaley, Clare L Griffin, Rebecca Lewis, Philip Mayles, Helen Mayles, Christopher D Scrase

Int J Radiat Oncol Biol Phys· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
P G Corrie, A Marshall, P D Nathan, P Lorigan, M Gore, Christopher Scrase

Ann Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial.
Antoine Kass-Iliyya, Gordana Jovic, Claire Murphy, Cyril Fisher, Isabel Syndikus, Christopher D Scrase

Eur Urol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial.
James M Wilson, David P Dearnaley, Isabel Syndikus, Vincent Khoo, Alison Birtle, Christopher Scrase

Int J Radiat Oncol Biol Phys· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.
Robert A Huddart, Alison Birtle, Lauren Maynard, Mark Beresford, Jane Blazeby, Christopher Scrase

BJU Int· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
David Dearnaley, Isabel Syndikus, Helen Mossop, Vincent Khoo, Alison Birtle, Christopher Scrase

Lancet Oncol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.
Ruth E Langley, Howard G Kynaston, Abdulla A Alhasso, Trinh Duong, Edgar M Paez, Christopher D Scrase

Eur Urol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.
Michel Bolla, Philippe Maingon, Christian Carrie, Salvador Villa, Petros Kitsios, Christopher Scrase

J Clin Oncol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Anna Wilkins, Helen Mossop, Isabel Syndikus, Vincent Khoo, David Bloomfield, Christopher Scrase

Lancet Oncol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation Therapy.
Victoria A Harris, John Staffurth, Olivia Naismith, Alikhan Esmail, Sarah Gulliford, Christopher Scrase

Int J Radiat Oncol Biol Phys· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality assurance for the EORTC 22071-26071 study: dummy run prospective analysis.
Alysa Fairchild, Johannes A Langendijk, Sandra Nuyts, Christopher Scrase, Milan Tomsej

Radiat Oncol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.
David P Dearnaley, Gordana Jovic, Isabel Syndikus, Vincent Khoo, Richard A Cowan, Christopher D Scrase

Lancet Oncol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Squamous cell carcinoma of the temporal bone: clinical outcomes from radical surgery and postoperative radiotherapy.
Liam Masterson, Maral Rouhani, Neil P Donnelly, James R Tysome, Parag Patel, Christopher Scrase

Otol Neurotol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial.
David Dearnaley, Isabel Syndikus, Georges Sumo, Margaret Bidmead, David Bloomfield, Christopher Scrase

Lancet Oncol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Christopher M Nutting, James P Morden, Kevin J Harrington, Teresa Guerrero Urbano, Shreerang A Bhide, Christopher Scrase

Lancet Oncol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensity modulated radiotherapy (IMRT) in the management of locally advanced oropharyngeal squamous cell carcinomata (SCC): disease control and functional outcome using the therapy outcome measure (TOM) score--report from a single U.K. institution.
Charlotte J Ingle, Kent Yip, Valerie Caskie, Catherine Dyson, Amanda Ford, Christopher D Scrase

Head Neck Oncol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group.
Philip Poortmans, Alberto Bossi, Katia Vandeputte, Mathieu Bosset, Raymond Miralbell, Christopher Scrase

Radiother Oncol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis